Immunotherapy targeting PD-1/PD-L1 exerts antitumor effects in several malignant tumors, and we expected this to be demonstrated in thymic cancers, especially in patients with thymic carcinoma insensitive to chemotherapy. This evidence concerns the gene CD274 and thymic carcinoma.